For Komipharm Pharmaceuticals, one of the largest manufacturers of Anti Cancer medicines in Asia

TERRASSA, BARCELONA, SPAIN, January 31, 2014 /EINPresswire.com/ -- Telstar has successfully developed two high containment barrier systems for the Korean Komipharm Pharmaceuticals Co Ltd, one of the largest producers of products from anti-cancer drugs in human oral dosage form to veterinary medicines in Asia. The systems, one for API Sampling and the other for QC Sample Handling will be used in Komipharm's new facility, built in the South Korean city of Cheongwon, Chungcheongbuk-do. The purpose of the systems is to provide a high level of containment to protect operators during the manufacturing process using API’s (Active Pharmaceutical Ingredients). Additionally, the systems will be utilised in research in the biotechnology field aimed to develop vaccines by genetic technology.

Specifically designed for handling hazardous products, these containment systems run at negative pressure to the surrounding room providing operator protection during the manual product handling process and environmental protection for the product by virtue of the standard ISO 7 classification inside the Isolator.

This project has been carried out by the Technology Centre for Barrier Isolation Systems of Telstar, located in Dewsbury (UK).

For handling APIs containing raw arsenic or Sodium Arsenite

The two containment barrier systems developed by Telstar have been specially designed to handle API’s during pharmaceutical manufacturing and analytical testing of product containing raw arsenic. One of the Isolator systems is for API Sampling and the other for QC Sample Handling. Both systems are based around the Telstar standard containment range to optimise cost efficiency, thus minimising design and assembly hours. Because of the standard design, the routine maintenance and every day running procedures are simplified and more cost efficient. Additionally, many of the featured parts are common, versatile and inter-changeable, which enables the client to avoid the over stocking of spares.

The development of the isolator design took into account aesthetics, ease of cleaning and general maintenance together with operator safety / efficiency. Integration of internal equipment is made possible via simple glands and tri-clamp connections. The forethought of including a spare port provides provision for future add on services and can also be utilised for DOP testing of filters during annual service.

The API Sampling Isolator includes single sided operator access to the main working chamber with mobile frame and onboard main control panel. Seimens PLC/HMI, materials transfer chamber for continuous batch processing, an integrated weigh system, integral Telstar glove tester, safe change HEPA filtration, contained transfer port, vacuum system and temperature/RH monitoring, are specifically attributed to this process Isolator. The addition of double sided access within its main working chamber, graphic data management for critical data storage via a modbus link, sockets to power a density tester, friability tester, hardness tester, sieve shaker, moisture detection and PH meter, completes the main characteristics specifically attributed to the QC Sample Handling Isolator.

The barrier containment system supplied to Komipharm stands out by its simplicity regarding the base design and control system, coupled with optional accessory enhancement to offer flexibility and adaptation if required in the future. Ergonomically trialled base designs were employed ensuring suitability of the final design to the required operations. Whilst providing cost savings this approach ensures that a high containment solution with operator comfort of equal priority is achieved.

Komipharm International

Komipharm Pharmaceuticals Co Ltd is a top leading company founded in 1972, producing a wide range of medicines (biological and pharmaceuticals), natural extract food additives and bio-fertilizers. The Company steps forward in biotechnology field research to develop and improve genetic recombinant vaccines by genetic technology, diagnostic kits and anti-cancer drugs. Over 25% of annual turnover has been invested in R&D activities for the past 10 years to develop new biotech products.

Komipharm, which operates in ten countries in Asia and South America, has seven patented drugs, six pipeline product candidates and nearly twenty brand name registrations in various categories. Headquartered in Siheung, Gyeonggi-do, the company has two manufacturing facilities.

Marketing Dept
Telstar
+34 93 736 16 00
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.